Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.63 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.63 |
| ▸ | PARP11 | Q9NR21 | 5/20 | 0.63 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688148 | 1.00 | PARP1 (0.63) | PARP1PARP10PARP11TRPM2ACHE | |
| SCHEMBL9475835 | 0.83 | CDK5 (0.56) | PARP1PARP10PARP11ACHECYP19A1 | |
| SCHEMBL30825444 | 0.83 | CDK5 (0.56) | PARP1PARP10PARP11ACHECYP19A1 | |
| SCHEMBL18757309 | 0.83 | PARP1 (0.58) | PARP1PARP10PARP11TRPM2ACHE | |
| SCHEMBL7581574 | 0.83 | PARP1 (0.58) | PARP1PARP10PARP11TRPM2PDPK1 | |
| SCHEMBL4717294 | 0.82 | PARP1 (0.65) | PARP1PARP10PARP11TRPM2 | |
| SCHEMBL7581679 | 0.81 | PARP1 (0.56) | PARP1PARP10PARP11TRPM2ACHE | |
| SCHEMBL7582536 | 0.80 | PARP1 (0.62) | PARP1PARP10PARP11TRPM2 | |
| SCHEMBL9194197 | 0.80 | PARP1 (0.43) | PARP1ACHECYP19A1 | |
| SCHEMBL7586205 | 0.79 | PARP1 (0.65) | PARP1PARP10PARP11TRPM2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4554683-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | Lantern Pharma Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2024-09-12 | — | — | US | disclosed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023010119-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20220339179-A1 | TREATMENT OF HR DEFICIENT CANCER | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2022-10-27 | — | — | US | disclosed |
| EP-4028009-A1 | TREATMENT OF HR DEFICIENT CANCER | The Francis Crick Institute Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | INSTITUT CURIE (FR) | 2021-11-02 | — | — | US | disclosed |
| CN-113574171-A | Compositions and methods for treating cancer | IN8生物股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| WO-2005053662-A1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
| WO-2003070234-A9 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNIV CASE WESTERN RESERVE (US) | 2004-02-26 | — | — | WO | disclosed |
| US-6635677-B2 | Potentiating toxicity of 1,3-bis(chloroethyl)2-nitrosourea | CASE WESTERN RESERVE UNIVERSITY | 2003-10-21 | — | — | US | disclosed |
| WO-2003070234-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20020198264-A1 | Methoxyamine combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2002-12-26 | — | — | US | disclosed |
| US-6465448-B1 | TREATING TUMORS RESISTANT TO TEMOZOLOMIDE ALONE | CASE WESTERN RESERVE UNIVERSITY | 2002-10-15 | — | — | US | disclosed |
| WO-2001012199-A2 | METHOXYAMINE POTENTIATION OF TEMOZOLOMIDE ANTI-CANCER ACTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2001-02-22 | — | — | WO | disclosed |
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5177075-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | PARP1, PARP2, PARP3 | PARP1 1/4885PARP10 14/4885PARP11 4/4885 |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | PARP10, PARP1, PARP3 | PARP1 2/4885PARP10 1/4885PARP11 4/4885 |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | PARP1, PARP2, PARP11 | PARP1 1/4885PARP10 8/4885PARP11 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.